Diabetes, Digestive, Kidney Extramural Research - Research Projects
Active
- Assistance listing
- 93.KRP
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- Not on record
Program facts
- Treasury account
-
- 75-0884-0-1-552
Program details come from SAM.gov Assistance Listings. Updated .
About this program
The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), funds extramural basic and clinical research projects under Assistance Listing 93.KRP to advance understanding of diabetes, digestive, kidney, endocrine, metabolic, hematologic, liver, nutrition, obesity, and urologic diseases, with project proposals subject to competitive peer review and merit-based funding determination.
NIDDK supports research across a broad portfolio of disease mechanisms and therapeutic areas. In diabetes, endocrine, and metabolic diseases, the program funds studies on etiology, pathogenesis, prevention, diagnosis, and treatment of diabetes mellitus and its complications; hormone secretion and regulation; signal transduction; and inherited metabolic disorders including cystic fibrosis. For digestive disease and nutrition, NIDDK funds genetics and genomics of the gastrointestinal tract, liver, and pancreas; bariatric surgery and clinical obesity research; liver disease complications including fibrosis, inflammation, fatty liver disease, viral hepatitis, and liver cancer; gastrointestinal mucosal immunology; and nutrition-related complications of infectious disease. The program funds predominantly Project Grants, with renewal awards determined through competitive reapplication and extensions considered upon request; Project Grant timelines extend 6 to 9 months.
Eligible applicants include universities, colleges, medical and dental schools, schools of public health, hospitals, state and local health departments, and other public or private nonprofit and for-profit institutions. Individuals with the necessary skills, knowledge, and resources may serve as Program Directors or Principal Investigators in collaboration with an eligible organization.
Applications undergo initial peer review for scientific merit by an appropriate review panel and the National Diabetes and Digestive and Kidney Diseases Advisory Council. Reviewers assess scientific merit and significance, technical adequacy of experimental design, investigator competency, adequacy of facilities and resources, necessity of budget components, and relevance to announced program objectives. The source does not provide recent grant award data, award economics, or information on currently open grant opportunities.
Objective and description
- Objective
To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic ar
- Description
To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved prevention, diagnosis, and treatment of diabetes, digestive, and kidney diseases. NIDDK programmatic areas include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases. Specific programs areas of interest include: (a) For diabetes, endocrine, and metabolic diseases: Fundamental and clinical studies on etiology, pathogenesis, prevention, diagnosis, treatment and cure of diabetes mellitus and its complications; Normal and abnormal function of the pituitary, thyroid, parathyroid, adrenal, and other hormone secreting glands; Hormonal regulation of bone, adipose tissue, and liver; fundamental aspects of signal transduction, including action of hormones, coregulators, and chromatin remodeling proteins; Hormone biosynthesis, secretion, metabolism, and binding; hormonal regulation of gene expression and the role(s) of selective receptor modulators as partial agonists/antagonists of hormone action; Fundamental studies relevant to metabolic disorders including membrane structure, function, and transport phenomena and enzyme biosynthesis; basic and clinical studies on etiology, pathogenesis, prevention, and treatment of inherited metabolic disorders (e.g. cystic fibrosis). (b) For digestive disease and nutrition: Genetics and genomics of the GI tract and its diseases; Genetics and genomics of liver/pancreas and diseases; Genetics and genomics of nutrition and obesity; Bariatric surgery; Clinical nutrition and obesity research; Liver disease complications; Fatty liver disease; Genetic liver disease; HIV and liver; Cell injury, repair, fibrosis and inflammation in the liver; Liver cancer; Liver transplantation; Pediatric liver disease; Viral hepatitis and infectious diseases; Gastrointestinal and nutrition effects of AIDS; Gastrointestinal mucosal and immunology; Gastrointestinal motility; Basic neurogastroenterology; Gastrointestinal development; Gastrointestinal epithelial biology; Gastrointestinal inflammation; Digestive diseases epidemiology and data systems; Nutritional epidemiology and data systems; Autoimmune liver disease; Bile, Bilirubin and cholestasis; Bioengineering and biotechnology related to digestive diseases, liver, nutrition and obesity; Liver cell and molecular biology; Developmental biology and regeneration; Drug-induced liver disease; Gallbladder disease and biliary diseases; Exocrine pancreas biology and diseases; Gastrointestinal neuroendocrinology; Gastrointestinal transport and absorption; Nutrient metabolism; Pediatric clinical obesity; Digestive diseases clinical trials; Liver clinical trials; Obesity prevention and treatment; Obesity and eating disorders. (c) For kidney, urologic and hematologic diseases: Kidney cell biology, development, physiology, and pathophysiology studies; Genetics of kidney disorders; Immune mechanisms of kidney disease; Kidney disease as a complication of diabetes; Effects of drugs, nephrotoxins and environmental toxins on the kidney; Mechanisms of kidney injury repair; Improved diagnosis, prevention and treatment of chronic kidney disease and end-stage renal disease; Improved approaches to maintenance dialysis therapies; Basic studies of lower urinary tract cell biology, development, physiology, and pathophysiology; Clinical studies of bladder dysfunction, incontinence, pyelonephritis, interstitial cystitis, benign prostatic hyperplasia, urolithiasis, and vesicoureteral reflux; Development of novel diagnostic tools and improved therapies, including tissue engineering strategies for urologic disorders; Research on hematopoietic cell differentiation; metabolism of iron overload and deficiency; Structure, biosynthesis and genetic regulation of hemoglobin; Research on etiology, pathogenesis, and therapeutic modalities for the anemia of inflammation and chronic diseases.
Eligibility
- Applicant eligibility
Eligible Organizations: Universities, colleges, medical, dental and nursing schools, schools of public health, laboratories, hospitals, State and local health departments, other public or private institutions, both non-profit and for-profit, and individuals who propose to establish, expand, and improve research activities in health sciences and related fields. Eligible Individuals (Program Director/Principal Investigator): Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.
- Beneficiary eligibility
Health professionals, graduate students, health professional students, scientists, and researchers, any nonprofit or for-profit organization, company, or institution engaged in biomedical research. Program Director(s)/Principal Investigator(s): Although no degree of education is either specified or required, nearly all successful applicants have doctoral degrees in one of the sciences or professions.
- Uses of assistance
Health/Medical, Higher Education (includes Research): Project Grants provide funds for salaries, equipment, supplies, travel, and other expenses associated with scientific investigation relevant to program objectives.
- Use restrictions
Specific Restrictions Determined at NOFO Level
How to apply
- Criteria for selecting proposals
The major elements in evaluating proposals include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; (2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives.
- Award procedure
Grant applications are reviewed initially for scientific merit by an appropriate peer review panel and by the National Diabetes and Digestive and Kidney Diseases Advisory Council composed of leaders in medical science, education, and public affairs. Approved applications will compete on a merit basis for available funds. Successful applicants are sent a Notice of Grant Award.
- Time to approval or disapproval
Other - Project Grants: From 6 to 9 months.
- Renewals
Project Grants: Renewals are determined by competitive application and review. Extensions considered upon request.
- Appeals
A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page https://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-064.html.
Grant opportunities
| Opportunity | Status | Posted | Applications due |
|---|---|---|---|
| Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed) | Forecasted | — |
Quick answers
What is Assistance Listing 93.KRP?
Assistance Listing 93.KRP is Diabetes, Digestive, Kidney Extramural Research - Research Projects, a federal grant program run by National Institutes of Health (Department of Health and Human Services).
What is the CFDA number for Diabetes, Digestive, Kidney Extramural Research - Research Projects?
Its CFDA number is 93.KRP: Assistance Listing numbers were called CFDA numbers before 2018.
Are there open grant opportunities under 93.KRP?
1 listed opportunity under 93.KRP is open or forecasted. The latest, Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed), was posted on November 5, 2026.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program